Shares in GB Group PLC (LSE:GBG) fell 9% on Tuesday as investors reacted nervously to its full-year outlook, despite management confirming that ...

The internet is a great tool for advancing knowledge and attaining information. We have an endless database at our fingertips, with sources answering any question you might think of. Whether you ...

The Australian sharemarket is set for a flat open, with ASX 200 futures down just 1 point (-0.01%) at 8:30 am AEST this morning. The local benchmark enters today’s session hovering near record ...

Diversifying an investment portfolio is crucial for mitigating risks and maximizing returns. Digital assets, including ...

Creo Medical Group PLC CEO Craig Gulliford talked with Proactive about the company’s strong performance in 2024 and strategic plans for 2025.

Nationwide Building Society recorded its highest ever year for growth in mortgage lending and returned £2.8 billion to its members, including £1 ...

Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is ...

Sprott Asset Management CEO John Ciampaglia talked with Proactive's Stephen Gunnion about the significant developments shaping the uranium sector, following recent executive orders from US ...

FTSE 100 falls 52 points Kingfisher returns to growth in first quarter News also from Pets at Home, Softcat, C&C and Rentokil Thames Water hit with Ofwat's highest ever fine 4.59pm: FTSE closes lower ...

UBS has downgraded Telstra Corporation Ltd (ASX:TLS) from Buy to Neutral and cut its price target to $4.50 from $4.60, citing limited upside as the share price nears fair value. While its investor ...

Shares in Mineral Resources Ltd (ASX:MIN) fell over 2% to $23.21 after the company downgraded its 2024–25 iron ore shipment guidance to 7.8–8 million ...

Prescient Therapeutics Ltd CEO James McDonnell talked with Proactive about the initiation of a Phase 2A clinical trial for the company’s lead candidate, PTX-100, targeting relapsed or refractory ...